Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Carsten Brunn
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Beta
- 0.65
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.62
Financials
Revenue
$0.00-100.0%Net Income
$13.72MEBITDA
$17.40MFree Cash Flow
$-20.90MEPS (diluted)
$0.46Shares Outstanding (diluted)
29.86M+5836.6%Operating Expenses
$29.16MCash & Debt
$147.61MRevenue by Segment (annual)
$2.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.80M | $-130.30M | $-5.02 |
| 2024 | $38.91M | $-77.42M | $-3.29 |
| 2023 | $26.00M | $-219.71M | $-49.76 |
| 2022 | $110.78M | $35.38M | $7.33 |
| 2021 | $85.08M | $-25.69M | $-6.74 |
| 2020 | $16.60M | $-68.88M | $-20.42 |
| 2019 | $6.68M | $-55.35M | $-36.46 |
| 2018 | $903.0K | $-65.34M | $-87.55 |
| 2017 | $207.0K | $-65.32M | $-95.94 |
| 2016 | $8.08M | $-36.21M | $-103.52 |
| 2015 | $6.01M | $-25.17M | $-75.79 |
| 2014 | $3.04M | $-12.88M | $-38.17 |
Valuation
RNAChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·22d ago·Negative
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company's common stock with an exercise p…
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment
View source ↗ - Newsglobenewswire.com·46d ago·Negative
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees.
View source ↗ - Newsglobenewswire.com·51d ago·Negative
Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
View source ↗
Earnings
Thu, Nov 5(in 11 days)
Consensus estimate $-1.02 per share
Typical surprise -11.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.46 vs $-0.88beat
- Thu, Apr 30$-1.46 vs $-0.84miss
- Mon, Mar 9$-1.38 vs $-0.82miss
- Thu, Nov 6$-1.38 vs $-0.81miss
- Thu, Aug 7$0.50 vs $-0.76beat
- Thu, May 8$-0.68 vs $-0.61miss
Estimates and results for RNAC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RNAC officers and directors.
- Bought
- $3.5m
- Sold
- $869k
17 trades
15 trades
- Brunn Carstensold
- Miljkovic Milossold
- Davis Blainesold
- Barabe Timothy Cbought
- Springer Timothy Abought
- Springer Timothy Abought
- Springer Timothy Abought
- Springer Timothy Abought
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RNAC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.